CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 
 

RVMD's Capital Expenditures Growth by Quarter and Year

Revolution Medicines Inc 's Capital Expenditures results by quarter and year




RVMD Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2.88 1.18 1.17
III Quarter September 2.54 3.53 0.45 0.69
II Quarter June 1.12 2.53 1.31 0.47
I Quarter March 1.76 1.89 3.58 0.60
FY   5.42 10.83 6.52 2.93



RVMD Capital Expenditures third quarter 2023 Y/Y Growth Comment
Revolution Medicines Inc reported fall in Capital Expenditures in the third quarter 2023 by -28.19% to $ 2.54 millions, from the same quarter in 2022.
The drop in the third quarter 2023 Revolution Medicines Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures rise of 35.53%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Capital Expenditures growth. While Revolution Medicines Inc ' s Capital Expenditures drop of -28.19% ranks overall at the positon no. 210 in the third quarter 2023.




RVMD Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 144.07 % 0.85 % -
III Quarter September -28.19 % 684.44 % -34.78 % -
II Quarter June -55.73 % 93.13 % 178.72 % -
I Quarter March -6.88 % -47.21 % 496.67 % -
FY   - 66.1 % 122.53 % -

Financial Statements
Revolution Medicines Inc 's third quarter 2023 Capital Expenditures $ 2.54 millions RVMD's Income Statement
Revolution Medicines Inc 's third quarter 2022 Capital Expenditures $ 3.53 millions Quarterly RVMD's Income Statement
New: More RVMD's historic Capital Expenditures Growth >>


RVMD Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -18.41 % 162.22 % 69.57 %
III Quarter September 126.34 % 39.53 % -65.65 % 46.81 %
II Quarter June -36.36 % 33.86 % -63.41 % -21.67 %
I Quarter March -38.89 % 60.17 % 205.98 % -
FY (Year on Year)   - 66.1 % 122.53 % -




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #28
Overall #210

Capital Expenditures Y/Y Growth Statistics
High Average Low
122.57 % 35.53 % -48.25 %
(Dec 31 2021)   (Mar 31 2021)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #28
Overall #210
Capital Expenditures Y/Y Growth Statistics
High Average Low
122.57 % 35.53 % -48.25 %
(Dec 31 2021)   (Mar 31 2021)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Revolution Medicines Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
206.16 % 35.54 % -65.4 %
(Mar 31 2021)  


RVMD's III. Quarter Q/Q Capital Expenditures Comment
Revolution Medicines Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 126.34%, to $ 2.54 millions, from $1.12 millions in the second quarter.
Revolution Medicines Inc is impressively improving, not only reporting above average increase, and additionally accelerating rate.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Capital Expenditures growth. While Revolution Medicines Inc 's Capital Expenditures growth quarter on quarter, overall rank is 100.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #17
Overall #100
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #17
Overall #100
Capital Expenditures Q/Q Growth Statistics
High Average Low
206.16 % 35.54 % -65.4 %
(Mar 31 2021)  


RVMD's III. Quarter Q/Q Capital Expenditures Comment
Revolution Medicines Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 126.34%, to $ 2.54 millions, from $1.12 millions in the second quarter.
Biotechnology & Pharmaceuticals company is impressively improving, with reporting higher then normal gain, and also improving speed.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Capital Expenditures growth. While Revolution Medicines Inc 's Capital Expenditures growth quarter on quarter, overall rank is 100.


Revolution Medicines Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 8.29 $ 9.28 $ 10.69 $ 10.82 $ 9.12
Y / Y Capital Expenditures Growth (TTM) -9.15 % 53.3 % 120.86 % 65.69 % 40.05 %
Year on Year Capital Expenditures Growth Overall Ranking # 648 # 1026 # 1689 # 219 # 892
Seqeuential Capital Expenditures Change (TTM) -10.67 % -13.17 % -1.21 % 18.56 % 50.74 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 519 # 574 # 1797 # 1239 # 223




Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2023 Revolution Medicines Inc reported a decrease in Capital Expenditures by -9.15% year on year, to $8 millions, compare to the 53.3% growth at Jun 30 2023.

In the Healthcare sector 99 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 648, from total ranking in previous quarter at 1026.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
122.57 %
35.53 %
-48.25 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 100
Overall # 648

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
122.57 %
35.53 %
-48.25 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 84
S&P 500 # 519
Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2023 Revolution Medicines Inc reported a decrease in Capital Expenditures by -9.15% year on year, to $8 millions, compare to the 53.3% growth at Jun 30 2023.

In the Healthcare sector 99 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 648, from total ranking in previous quarter at 1026.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
122.57 %
35.53 %
-48.25 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 100
Overall # 648

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
122.57 %
35.53 %
-48.25 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 84
S&P 500 # 519




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
RVMD's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for RVMD's Competitors
Capital Expenditures Growth for Revolution Medicines Inc 's Suppliers
Capital Expenditures Growth for RVMD's Customers

You may also want to know
RVMD's Annual Growth Rates RVMD's Profitability Ratios RVMD's Asset Turnover Ratio RVMD's Dividend Growth
RVMD's Roe RVMD's Valuation Ratios RVMD's Financial Strength Ratios RVMD's Dividend Payout Ratio
RVMD's Roa RVMD's Inventory Turnover Ratio RVMD's Growth Rates RVMD's Dividend Comparisons



Companies with similar Capital Expenditures decrease for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com